[Pre-Aug 2018] IMSCAR

  1. Web publication/site › Research
  2. Published

    Improving Outcomes for People with Sarcoma - Analysis of Potential Economic Impact.

    Linck, P. G., Linck, P., Hughes, D. A. & Edwards, R. T., 22 Mar 2006

    Research output: Non-textual formWeb publication/site

  3. Published

    Improving Outcomes in Children and Young People with Cancer: Analysis of the Potential Economic Impact of the Guidance.

    Linck, P. G., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 24 Aug 2005

    Research output: Non-textual formWeb publication/site

  4. Published
  5. Working paper › Research
  6. Published

    Measuring Later Life Social Exclusion in Understanding Society

    MacLeod, C., Ross, A., Windle, G., Netuveli, G. & Sacker, A., 27 Jun 2016, The International Centre for Lifecourse Studies in Society and Health (ICLS): University College London, p. 1-14, 14 p.

    Research output: Working paper

  7. Other report › Research › Not peer-reviewed
  8. Published

    The evaluation of the National Exercise Referral Scheme in Wales

    Murphy, S. M., Raisanen, L., Moore, G., Edwards, R., Linck, P., Hounsome, N., Williams, N., Din, N. & Moore, L., 2010, Welsh Government. (Social research; no. Number: 07/2010)

    Research output: Book/ReportOther report

  9. Commissioned report › Research › Peer-reviewed
  10. Published

    Byw yn dda yn hirach: Y ddadl economaidd dros fuddsoddi yn iechyd a llesiant pobl hŷn yng Nghymru

    Edwards, R., Spencer, L., Bryning, L. & Anthony, B., 30 Jul 2018, 68 p.

    Research output: Book/ReportCommissioned reportpeer-review

  11. Published
  12. Published

    Lles mewn gwaith: Y dadleuon economaidd dros fuddsoddi mewn iechyd a lles y gweithlu yng Nghymru

    Edwards, R. T., Spencer, L., Anthony, B. & Bryning, L., 17 Oct 2019, Bangor : Bangor University. 64 p.

    Research output: Book/ReportCommissioned reportpeer-review

  13. Published

    Transforming Young Lives across Wales: The Economic Argument for Investing in Early Years

    Edwards, R., Bryning, L. & Lloyd Williams, H., 13 Oct 2016, Prifysgol Bangor University. 110 p.

    Research output: Book/ReportCommissioned reportpeer-review

  14. Published

    Wellness in work: The economic arguments for investing in the health and wellbeing of the workforce in Wales

    Edwards, R. T., Spencer, L., Anthony, B. & Bryning, L., 17 Oct 2019, Bangor: Bangor University. 64 p.

    Research output: Book/ReportCommissioned reportpeer-review

  15. Commissioned report › Research › Not peer-reviewed
  16. Published
  17. Published

    A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.

    Hughes, D. & Hughes, D. A., 1 Jan 2001, 2001 ed. Unknown.

    Research output: Book/ReportCommissioned report

  18. Published

    A study of the effects of the Carers Strategy in Wales on the needs of carers and the services they receive

    Seddon, D., Robinson, C. A., Russell, I. T., Woods, R. T., Tommis, Y., Reeves, C., Perry, J. K. & Boyle, M., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  19. Published

    AWMSG criteria for appraising new medicines.

    Hughes, D. & Hughes, D. A., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  20. Published
  21. Published
  22. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/ReportCommissioned report

  23. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/ReportCommissioned report

  24. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  25. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  26. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  27. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  28. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  29. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  30. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  31. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  32. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  33. Published
  34. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  35. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/ReportCommissioned report

  36. Published
  37. Published
  38. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  39. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  40. Published
  41. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  42. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  43. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  44. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Trabectedin (Yondelis) for advanced soft tissue sarcoma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  45. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/ReportCommissioned report

  46. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  47. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Co-careldopa intestinal gel (Duodopa).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  48. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Darunavir (Prezista)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  49. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  50. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  51. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Dexrazoxane (Savene)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  52. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  53. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Idursulfase (Elaprase)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  54. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

  55. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Tipranavir (Aptivus).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/ReportCommissioned report

Previous 1 2 3 4 5 6 7 8 ...16 Next